Low-dose parenteral busulfan provides an extended window for the infusion of hematopoietic stem cells in murine hosts

This publication has 37 references indexed in Scilit:

• Therapeutic Options for Patients with Severe β-Thalassemia: The Need for Globin Gene Therapy
  Human Gene Therapy, 2007
• Correction of the disease phenotype in canine leukocyte adhesion deficiency using ex vivo hematopoietic stem cell gene therapy
  Blood, 2006
• Effects of busulfan dose escalation on engraftment of infant rhesus monkey hematopoietic stem cells after gene marking by a lentiviral vector
  Experimental Hematology, 2006
• Busulfan pharmacokinetics, toxicity, and low-dose conditioning for autologous transplantation of genetically modified hematopoietic stem cells in the rhesus macaque model
  Experimental Hematology, 2006
• Low dose busulfan facilitates chimerism and tolerance in a murine model
  Transplant Immunology, 2006
• Once-daily intravenous busulfan and fludarabine: clinical and pharmacokinetic results of a myeloablative, reduced-toxicity conditioning regimen for allogeneic stem cell transplantation in AML and MDS
  Blood, 2004
• Hematopoietic Cell Transplantation for Benign Hematological Disorders and Solid Tumors
  Hematology-American Society Hematology Education Program, 2003
• Marrow Transplantation for Acute Nonlymphocytic Leukemia after Treatment with Busulfan and Cyclophosphamide
  New England Journal of Medicine, 1983
• The Action of Chlorambucil (CB. 1348) and Busulphan (Myleran) on the Haemopoietic Organs of the Rat
  British Journal of Haematology, 1958
• MYLERAN IN CHRONIC MYELOID LEUKÆMIA CHEMICAL CONSTITUTION AND BIOLOGICAL ACTION
  The Lancet, 1953